AEON Posts Q3 Net Income of $2.5M on Warrant Remeasurement; Cash Runway to Q2 2027
AEON is trading near its 52-week low of $0.127 (11% above the low) on light trading volume (0.1× avg).
Summary
AEON reported Q3 2026 net income of $2.5 million, driven by a $7.0 million non-cash warrant fair-value gain rather than operations, with $11.4 million of cash at quarter-end plus about $6.2 million of warrant proceeds funding operations into Q2 2027. FDA Type 2b minutes and a submitted CMAP study IND support a Q1 2027 study start.
Key Events · Earnings and Guidance · AEON
-
Q3 Profit Is Non-Cash
Q3 2026 net income of $2.465 million versus a $4.538 million loss a year earlier, driven by a $7.014 million non-cash gain on warrant fair-value remeasurement; the operating loss was $4.483 million.
-
Cash Runway Into Q2 2027
Cash and equivalents were $11.4 million at September 30, 2026, which excludes about $6.2 million of milestone-warrant proceeds received in Q4; together the company expects funding into Q2 2027.
-
FDA Type 2b Path Clarified
FDA minutes agreed in principle with a two-stage CMAP pharmacodynamic study design and indicated Daewoong's prior comparative clinical studies can be submitted as supportive evidence, subject to scientific bridging to U.S.-licensed BOTOX.
-
CMAP Study IND Submitted
AEON submitted the IND for the comparative CMAP pharmacodynamic study and plans to initiate it in Q1 2027, with a multi-lot forced degradation comparability study planned for the first half of 2027.
Analysis · AEON · Life Sciences
The headline profit is accounting, not operations: a $7.0 million non-cash gain from remeasuring warrant liabilities drove $2.5 million of Q3 net income, while the business still lost $4.5 million from operations. What actually matters is the balance sheet and the regulatory path. Cash stood at $11.4 million on September 30, and adding the roughly $6.2 million of milestone-warrant proceeds received in Q4 extends funding into the second quarter of 2027 — enough to reach the planned Q1 2027 start of the CMAP pharmacodynamic study but not much beyond it. With the FDA's Type 2b minutes, AEON gains a clearer, cheaper route to a BOTOX biosimilar filing by leaning on analytical and pharmacodynamic data plus Daewoong's existing clinical studies, and the sequence coverage improvement to about 98% strengthens that analytical case. The company remains dependent on raising more capital before mid-2027.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AEON was trading at $0.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $0.13 to $1.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.